Investing.comDoubao · 实盘不做把握 4/10不做原因:风险收益比不佳
北京时间·🕒 发布 20:04:31·⟳ 抓取 20:05:50 +1m19s·⚡ 决策 10-26 20:09:27 +3m37s·18.9 小时前
CEL-SCI公布Multikine头颈癌三期失败试验的生物标志物亚组回顾性分析，称5年生存率73.4%对45.0%，并拟另启212人注册研究
这是一项在主要终点已失败的三期试验上做的小样本（n=114）事后生物标志物亚组回顾性分析，属假设生成性证据而非可获批依据；公司自己都需另启212例注册研究，读数在数年后，Multikine未获批、零产品收入。标的为约2,900万美元市值、股价约1.6美元的微盘股，日均成交额仅约40万–70万美元，盘前仅200余股成交、约+1.8%，缺乏真实承接。新闻稿+AI转写+冷门学术会议的组合典型地缺乏可交易的正期望值，潜在消息炒作波动不构成可执行的方向edge。
📄 原文Investing.com↗ 原文
CEL-SCI reports survival data from Multikine cancer study
Five things to watch in markets in the week ahead VIENNA, Va. - CEL-SCI Corporation (NYSE American:CVM) announced resul…
不做 CEL-SCI Corporation（CVM.US）
数据来自已失败三期的n=114事后生物标志物亚组，不可用于获批，公司须另启数年周期的212例注册研究，无近期收入/获批催化；约2,900万美元市值、日均成交仅约40万–70万美元的微盘低价股，盘前200余股约+1.8%无承接，新闻稿+AI转写+冷门会议缺乏可交易正edge，不参与消息脉冲。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
CEL-SCI在一项已失败三期的114例事后亚组中读出亮眼生存数据并拟另开注册研究，但该证据不可获批、新研究读数数年之后、无产品收入，且标的是流动性极差的微盘低价股，事件边际不具备可交易的风险回报，回避。
🔎 新鲜度:最早出现 2026-10-26 · 扩散 low · price-in 风险 medium ↗
关键理由
- 亚组数据本身统计显著（HR 0.34、p=0.0012）且安全性良好，对单资产微盘股是名义正面信息
- 但这是已失败三期的事后小样本亚组，只能支持另做验证性研究，不改变近期获批/收入路径
主要风险
- 事后亚组与多重比较可能高估疗效，新注册研究存在重演三期失败、读数需数年的风险
- 约2,900万美元市值、日均成交约40万–70万美元的微盘股，新闻稿驱动的脉冲式炒作与后续融资稀释风险并存，买卖价差大、滑点高
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
Web搜索服务本轮不可用（invalid_api_key），无法重新核验三期失败原文；但本条正文明确表述为‘已完成三期的新分析’且Multikine仍为未获批在研疗法、需另做212例注册研究，间接确认当前并无获批依据。
检索:Multikine Phase 3 failed primary endpoint overall survival 2021 CEL-SCI FDA - 做多前查反向 · 来源 kb_search · 日期 2026-10-26 · 影响 weakens
内部库无CVM资金/研报覆盖，约2,900万美元市值的微盘公司开展全新注册研究高度依赖后续融资，稀释与执行风险无法排除。
检索:CVM cash runway financing dilution registration study 212 patients
先例如何影响了这次决策
对本次决策的影响:不改变结论：失败三期的事后亚组+另开新研究这一性质本身决定无近期可交易催化，故AVOID
方向:无可用对齐先例
涨幅量级:无法以先例校准幅度
形态:无先例支持见光死或追涨判断
工具执行结果 · 成功 2 · 降级 1 · 失败 1 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 241 ms
{"result": "search_processed_events:agent query=`cel-sci 212-patient us registration study multikine results rome | cel-sci multikine phase 3 biomarker subgroup survival head and neck cancer | cvm multikine 5-year overall surviva`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 69.9/72 小时、2990 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 - web_search 失败 doubao_search · 907 ms
invalid_api_key: web_search 失败:豆包搜索 invalid_api_key invalid api key - stock_quote 降级 stock_tools HTTP · 749 ms
{ - kb_search 成功 stock_tools HTTP · 1,362 ms
{
原文全文
展开原文 · 2,036 字
Five things to watch in markets in the week ahead
VIENNA, Va. - CEL-SCI Corporation (NYSE American:CVM) announced results from new analyses of its completed Phase 3 study of Multikine for head and neck cancer treatment, according to a press release statement.
The analyses focused on a patient population with locally advanced disease, no lymph node involvement and low or zero tumor PD-L1 expression. In this biomarker-selected group of 114 patients, the 5-year overall survival rate was 73.4% for patients receiving Multikine plus standard of care compared to 45.0% for standard of care alone. The hazard ratio was 0.34 with a p-value of 0.0012.
The data showed 38.0% of Multikine-treated patients experienced disease downstaging or tumor shrinkage before surgery, compared to 13.0% of patients receiving standard of care alone. The company reported this difference was statistically significant with a p-value of 0.003.
The median time to death was not reached for the Multikine group, while it was 50.6 months for the standard of care group.
A safety analysis across the broader Phase 3 trial showed no deaths attributed to Multikine. The treatment did not increase the incidence or severity of Grade 3 or Grade 4 adverse events relative to standard of care alone. Adverse events associated with pre-surgical Multikine administration were primarily local injection-site reactions that resolved following surgery.
The findings were presented by Chief Scientific Officer Dr. Eyal Talor at the 6th World Congress on Otology, Rhinology and Laryngology in Rome, Italy.
CEL-SCI plans to conduct a 212-patient U.S. Registration Study using these biomarker selection criteria with overall survival as the primary endpoint. The study is designed with approximately 97% statistical power to detect the survival effect observed in the target population.
Multikine is an investigational therapy that has not been approved by the FDA.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
VIENNA, Va. - CEL-SCI Corporation (NYSE American:CVM) announced results from new analyses of its completed Phase 3 study of Multikine for head and neck cancer treatment, according to a press release statement.
The analyses focused on a patient population with locally advanced disease, no lymph node involvement and low or zero tumor PD-L1 expression. In this biomarker-selected group of 114 patients, the 5-year overall survival rate was 73.4% for patients receiving Multikine plus standard of care compared to 45.0% for standard of care alone. The hazard ratio was 0.34 with a p-value of 0.0012.
The data showed 38.0% of Multikine-treated patients experienced disease downstaging or tumor shrinkage before surgery, compared to 13.0% of patients receiving standard of care alone. The company reported this difference was statistically significant with a p-value of 0.003.
The median time to death was not reached for the Multikine group, while it was 50.6 months for the standard of care group.
A safety analysis across the broader Phase 3 trial showed no deaths attributed to Multikine. The treatment did not increase the incidence or severity of Grade 3 or Grade 4 adverse events relative to standard of care alone. Adverse events associated with pre-surgical Multikine administration were primarily local injection-site reactions that resolved following surgery.
The findings were presented by Chief Scientific Officer Dr. Eyal Talor at the 6th World Congress on Otology, Rhinology and Laryngology in Rome, Italy.
CEL-SCI plans to conduct a 212-patient U.S. Registration Study using these biomarker selection criteria with overall survival as the primary endpoint. The study is designed with approximately 97% statistical power to detect the survival effect observed in the target population.
Multikine is an investigational therapy that has not been approved by the FDA.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
a2e1249b3d· 2026-10-26 20:09 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前